Announcements Trials
Browse Landscape

Phase

Phase NA 11Phase 2 5Phase 4 2Phase 1/2 2Phase 1 2Phase EARLY_PHASE1 1Phase 3 1

Status

Completed 4Unknown 1

Sponsor Class

OTHER 579INDUSTRY 131NIH 124NETWORK 58OTHER_GOV 5FED 2UNKNOWN 1

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5

Conditions

Breast Neoplasms 55Carcinoma, Non-Small-Cell Lung 33Stomach Neoplasms 28Colorectal Neoplasms 26Small Cell Lung Carcinoma 19Lung Neoplasms 18Rectal Neoplasms 16Pancreatic Neoplasms 14Neoplasms 14Neoplasm Metastasis 14Uterine Cervical Neoplasms 12Esophageal Neoplasms 12Ovarian Neoplasms 11Nasopharyngeal Carcinoma 11Carcinoma, Hepatocellular 11Recurrence 10Leukemia, Myeloid, Acute 10Melanoma 9Esophageal Squamous Cell Carcinoma 8Colonic Neoplasms 8Triple Negative Breast Neoplasms 7Lymphoma, Non-Hodgkin 7Head and Neck Neoplasms 7Hodgkin Disease 6Cholangiocarcinoma 6Adenocarcinoma of Lung 6Squamous Cell Carcinoma of Head and Neck 5Prostatic Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasms, Germ Cell and Embryonal 5

Interventions

Vinorelbine 3Gemcitabine 3Ifosfamide 2Thiotepa 1Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × OTHER_GOV × Lymphoma × Clear all
NCT03346096 2024-07-09

TEAM

Sheba Medical Center

Phase 2 Completed
50 enrolled
Lymphoid

Lymphoma

NCT00280878 2016-01-15

Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma

Bayside Health

Phase 2 Completed
12 enrolled
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin

NCT00163748 2016-01-08

Efficacy and Treatment Related Toxicity Study of a New Regimen for Lymphoma

Bayside Health

Phase 2 Completed
40 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin

NCT00163761 2016-01-08

Efficacy Study of Outpatient Therapy for Lymphoma

Bayside Health

Phase 2 Completed
90 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin

NCT01300156 2011-02-21

Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL)

National Cancer Center, Korea

Phase 2 Unknown
37 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡